Investor Presentaiton

Investor Presentation First nine months of 2018 Novo Nordisk's opportunity is in the large unmet needs across all therapy areas in scope DIABETES 425 million ~6% OBESITY 650 million ~2% HAEMOPHILIA ~425,000 ~50% People with diabetes People in good control People with obesity People medically treated People with haemophilia People living with constant pain Slide 31 OTHER SERIOUS CHRONIC DISEASES 80% of diagnosed NASH patients are obese and 35% have T2DM 70% of diabetes patients die from atherosclerotic CVD 40% of patients hospitalised for heart failure are diabetic ~50% of the total CKD population suffers from diabetic nephropathy NASH: Non-alcoholic steatohepatitis, T2DM: Type 2 diabetes mellitus, CVD: Cardiovascular disease, CKD: Chronic kidney disease Source: International Diabetes Federation; Diabetes Atlas 8th Edition 2017, IQVIA MIDAS 2017, World Federation of Haemophilia - Annual Global Survey 2016, Abera SF et al. Global, Regional, and National Burden of Cardiovascular Diseases for 10 Causes, 1990 to 2015, 2017; Heart Disease and Stroke Statistics, American Heart Association, 2017; Williams CD et al. Prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis among a largely middle-aged population utilising ultrasound and liver biopsy, 2011; Addressing the global burden of chronic kidney disease through clinical and translational research, 2014 novo nordisk

View entire presentation